| Oct 24 |
X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024
|
| Oct 1 |
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 18 |
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a favorite amongst institutional investors who own 51%
|
| Aug 28 |
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
|
| Aug 13 |
XFOR: First Commercial Sales of XOLREMDI™…
|
| Aug 10 |
X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
X4 Pharmaceuticals: Q2 Earnings Snapshot
|
| Aug 8 |
X4 Pharmaceuticals GAAP EPS of $0.45 beats by $0.46
|
| Aug 8 |
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
|
| Aug 7 |
X4 Pharmaceuticals Q2 2024 Earnings Preview
|
